» Authors » H Kosmehl

H Kosmehl

Explore the profile of H Kosmehl including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 134
Citations 904
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Sychra V, Esser D, Kosmehl H, Herold M
Dentomaxillofac Radiol . 2012 Jan; 42(3):27101530. PMID: 22241868
The most common manifestation of plasma cell neoplasms is multiple myeloma. Solitary and localized tumours in the form of solitary plasmacytoma of the bone or extramedullary plasmacytoma are rare. In...
2.
Gecks T, Junker K, Franz M, Richter P, Walther M, Voigt A, et al.
Clin Chim Acta . 2011 Jul; 412(21-22):1931-6. PMID: 21763295
Background: ECM remodelling during tumorigenesis entails the re-occurrence of different Tn-C(L) splicing variants. In patients with urothelial carcinoma of the urinary bladder (UBC), B and C domain containing Tenascin-C (B(+)...
3.
Fiedler W, Dahse R, Schlichter A, Junker K, Kosmehl H, Ernst G, et al.
Int J Oncol . 2011 May; 9(6):1227-32. PMID: 21541632
Telomerase activity and telomere length were analyzed in a total of 59 surgically removed primary renal cell carcinoma (RCC). The study includes tissue from the centre of the tumor, several...
4.
Franz M, Grun K, Richter P, Brehm B, Fritzenwanger M, Hekmat K, et al.
Histochem Cell Biol . 2010 Oct; 134(5):503-17. PMID: 20931338
Chronic cardiac rejection is represented by cardiac allograft vasculopathy (CAV) and cardiac interstitial fibrosis (CIF) known to cause severe complications. These processes are accompanied by remarkable changes in the cardiac...
5.
Wippermann J, Schumann D, Klemm D, Kosmehl H, Salehi-Gelani S, Wahlers T
Eur J Vasc Endovasc Surg . 2009 Feb; 37(5):592-6. PMID: 19231251
Objective: Tissue-engineered blood vessels (TEBVs) represent an innovative approach for overcoming reconstructive problems associated with extended vascular diseases by providing small-calibre vascular grafts. This study aimed to evaluate a novel...
6.
Dahse R, Driemel O, Schwarz S, Dahse J, Kromeyer-Hauschild K, Berndt A, et al.
Br J Cancer . 2009 Jan; 100(4):623-5. PMID: 19174819
Activating mutations within the epidermal growth factor (EGFR) tyrosine kinase domain identify non-small cell lung cancer patients with improved clinical response to tyrosine kinase inhibitor therapy. Recently, we identified two...
7.
Lesser T, Klinzing S, Schubert H, Kosmehl H
Eur J Med Res . 2008 Oct; 13(9):432-8. PMID: 18948235
Background: Videothoracoscopic lung sonography after partial fluid instillation could be a new method for endoscopic detection of lung lesions. Histopathological consequences of unilateral diagnostic or therapeutic lung flooding under bronchoalveolar...
8.
Kilian O, Dahse R, Alt V, Zardi L, Hentschel J, Schnettler R, et al.
Calcif Tissue Int . 2008 Jul; 83(2):101-11. PMID: 18663401
Fracture healing is a reparative physiological process, which proceeds in stages, each characterized by the predominant tissue in the fracture gap. The tissue matrix is continuously reorganized by cell migration,...
9.
Dahse R, Kosmehl H
Br J Cancer . 2008 Jun; 99(1):90-2. PMID: 18542074
Activating mutations within the epidermal growth factor receptor (EGFR) identify lung adenocarcinoma patients with improved clinical responses to tyrosine kinase inhibitors gefitinib and erlotinib. By screening salivary gland carcinoma, two...
10.
Driemel O, Kunkel M, Hullmann M, Kleinsasser N, Staudenmaier R, Muller-Richter U, et al.
HNO . 2008 Jan; 56(2):205-10. PMID: 18214406
Background: This study evaluated the performance of oral brush biopsies using standard morphological analysis and haematoxylin and eosin (HE) staining for detecting oral squamous cell carcinomas and their respective precursor...